Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
20
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director | 3 | $0 | $0 | 2025-07-25 |
| Koehler Maria | Director | 6 | $0 | $0 | 2024-06-07 |
| Wooster Richard | Director | 4 | $0 | $0 | 2024-06-07 |
| Dukes Iain D. | Director | 4 | $0 | $0 | 2024-06-07 |
| Hughes Owen | Director | 3 | $0 | $0 | 2024-06-07 |
| Bonita David P | Director | 44 | $14.68M | $0 | 2024-06-07 |
| Stampacchia Otello | Director | 8 | $0 | $0 | 2024-06-07 |
| FORMELA JEAN FRANCOIS | Director | 16 | $2.00M | $385.6K | 2024-06-07 |
| Germa Caroline | Chief Medical Officer | 1 | $0 | $0 | 2024-03-01 |
| Manfredi Mark | President & CEO | 3 | $0 | $0 | 2024-02-01 |
| Ecsedy Jeffrey | Chief Development Officer | 3 | $0 | $0 | 2024-02-01 |
| Marango Jotin | CFO & Head of Corp. Dev. | 3 | $0 | $0 | 2024-02-01 |
| OrbiMed Capital GP VI LLC | Director | 6 | $1.13M | $0 | 2023-08-04 |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | 12 | $0 | $26.8K | 2023-01-03 |
| Santillana Sergio L. | Chief Medical Officer | 2 | $0 | $0 | 2023-01-03 |
| Renaud Ronald C JR | Director | 2 | $0 | $0 | 2022-06-09 |
| Tessier Maude | Chief Business Officer | 7 | $0 | $0 | 2022-02-02 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 4 | $2.00M | $385.6K | 2021-12-14 |
| OrbiMed Genesis GP LLC | Director | 32 | $13.55M | $0 | 2021-03-30 |
| Atlas Venture Associates XI, LLC | 10% Owner | 7 | $0 | $0 | 2021-03-30 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director | A Award | 2025-07-25 | 2025-07-30 | 83,611 | $2.49 | $208.2K | 287,885 | SEC↗ |
| Hughes Owen | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Dukes Iain D. | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Wooster Richard | Director | A Award deriv | 2024-06-07 | 2024-06-10 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Germa Caroline | Chief Medical Officer | A Award deriv | 2024-03-01 | 2024-03-05 | 579,100 | — | $0 | 579,100 | SEC↗ |
| Manfredi Mark | President & CEO | A Award deriv | 2024-02-01 | 2024-02-02 | 320,000 | — | $0 | 320,000 | SEC↗ |
| Marango Jotin | CFO & Head of Corp. Dev. | A Award deriv | 2024-02-01 | 2024-02-02 | 181,000 | — | $0 | 181,000 | SEC↗ |
| Ecsedy Jeffrey | Chief Development Officer | A Award deriv | 2024-02-01 | 2024-02-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2023-08-04 | 2023-09-14 | 353,192 | — | $0 | 353,192 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | A Award deriv | 2023-08-04 | 2023-09-14 | 353,192 | — | $0 | 353,192 | SEC↗ |
| ORBIMED ADVISORS LLC | Director | A Award deriv | 2023-08-04 | 2023-09-21 | 353,192 | — | $0 | 353,192 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2023-08-04 | 2023-09-21 | 353,192 | — | $0 | 353,192 | SEC↗ |
| Bonita David P | Director | A Award | 2023-08-04 | 2023-09-14 | 153,121 | — | $0 | 2,251,218 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | A Award | 2023-08-04 | 2023-09-14 | 153,121 | — | $0 | 2,251,218 | SEC↗ |
| ORBIMED ADVISORS LLC | Director | A Award | 2023-08-04 | 2023-09-21 | 153,121 | — | $0 | 5,582,144 | SEC↗ |
| Bonita David P | Director | A Award | 2023-08-04 | 2023-09-21 | 153,121 | — | $0 | 5,582,144 | SEC↗ |
| Wooster Richard | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Hughes Owen | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Dukes Iain D. | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2023-06-09 | 2023-06-13 | 17,520 | — | $0 | 17,520 | SEC↗ |
| Manfredi Mark | President & CEO | A Award deriv | 2023-01-03 | 2023-01-05 | 220,000 | — | $0 | 220,000 | SEC↗ |
| Marango Jotin | CFO & Head of Corp. Dev. | A Award deriv | 2023-01-03 | 2023-01-05 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | A Award deriv | 2023-01-03 | 2023-01-05 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Ecsedy Jeffrey | Chief Development Officer | A Award deriv | 2023-01-03 | 2023-01-05 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Santillana Sergio L. | Chief Medical Officer | A Award deriv | 2023-01-03 | 2023-01-05 | 105,000 | — | $0 | 105,000 | SEC↗ |
| Hughes Owen | Director | A Award deriv | 2022-12-15 | 2022-12-19 | 35,040 | — | $0 | 35,040 | SEC↗ |
| Bonita David P | Director | P Buy | 2022-06-24 | 2022-06-24 | 96,035 | $5.37 | $515.7K | 2,098,097 | SEC↗ |
| Bonita David P | Director | P Buy | 2022-06-24 | 2022-06-24 | 65,965 | $4.37 | $288.3K | 2,002,062 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | P Buy | 2022-06-24 | 2022-06-24 | 96,035 | $5.37 | $515.7K | 2,098,097 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | P Buy | 2022-06-24 | 2022-06-24 | 65,965 | $4.37 | $288.3K | 2,002,062 | SEC↗ |
| Bonita David P | Director | P Buy | 2022-06-23 | 2022-06-24 | 23,419 | $3.71 | $86.9K | 1,936,097 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | P Buy | 2022-06-23 | 2022-06-24 | 23,419 | $3.71 | $86.9K | 1,936,097 | SEC↗ |
| Bonita David P | Director | P Buy | 2022-06-22 | 2022-06-24 | 66,806 | $3.55 | $237.2K | 1,912,678 | SEC↗ |
| OrbiMed Capital GP VI LLC | Director | P Buy | 2022-06-22 | 2022-06-24 | 66,806 | $3.55 | $237.2K | 1,912,678 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Wooster Richard | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Renaud Ronald C JR | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Dukes Iain D. | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2022-06-09 | 2022-06-13 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Marango Jotin | CFO & Head of Corp. Dev. | A Award deriv | 2022-04-25 | 2022-04-25 | 397,199 | — | $0 | 397,199 | SEC↗ |
| Manfredi Mark | President & CEO | A Award deriv | 2022-02-03 | 2022-02-04 | 238,900 | — | $0 | 238,900 | SEC↗ |
| Tessier Maude | Chief Business Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Ecsedy Jeffrey | Chief Development Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 59,360 | — | $0 | 59,360 | SEC↗ |
| Santillana Sergio L. | Chief Medical Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 70,400 | — | $0 | 70,400 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | A Award deriv | 2022-02-02 | 2022-02-04 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Wooster Richard | Director | A Award deriv | 2022-01-21 | 2022-01-25 | 29,200 | — | $0 | 29,200 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise deriv | 2022-01-18 | 2022-01-20 | 38,915 | — | $0 | 5,560 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise deriv | 2022-01-18 | 2022-01-20 | 8,265 | — | $0 | 28,963 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise deriv | 2022-01-18 | 2022-01-20 | 24,606 | — | $0 | 11,186 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise | 2022-01-18 | 2022-01-20 | 38,915 | $2.94 | $114.4K | 67,707 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise | 2022-01-18 | 2022-01-20 | 24,606 | $4.15 | $102.1K | 92,313 | SEC↗ |
| Tessier Maude | Chief Business Officer | M Exercise | 2022-01-18 | 2022-01-20 | 8,265 | $4.51 | $37.3K | 100,578 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise deriv | 2022-01-11 | 2022-01-12 | 964 | — | $0 | 24,473 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise | 2022-01-11 | 2022-01-12 | 964 | $2.15 | $2.1K | 45,439 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | S Sale | 2022-01-11 | 2022-01-12 | 964 | $12.00 | $11.6K | 44,475 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise deriv | 2022-01-10 | 2022-01-12 | 36 | — | $0 | 25,437 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | S Sale | 2022-01-10 | 2022-01-12 | 36 | $12.00 | $432 | 44,475 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise | 2022-01-10 | 2022-01-12 | 36 | $2.15 | $77 | 44,511 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Renaud Ronald C JR | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Dukes Iain D. | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 23,419 | — | $0 | 23,419 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2021-12-21 | 2021-12-23 | 13,419 | — | $0 | 13,419 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2021-12-14 | 2021-12-14 | 5,959 | $14.00 | $83.4K | 1,241,935 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | S Sale | 2021-12-14 | 2021-12-14 | 5,959 | $14.00 | $83.4K | 1,241,935 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2021-12-13 | 2021-12-14 | 8,330 | $14.64 | $122.0K | 1,247,894 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | S Sale | 2021-12-13 | 2021-12-14 | 8,330 | $14.64 | $122.0K | 1,247,894 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise deriv | 2021-12-10 | 2021-12-14 | 1,000 | — | $0 | 25,473 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | S Sale | 2021-12-10 | 2021-12-14 | 11,989 | $15.03 | $180.2K | 1,256,224 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | S Sale | 2021-12-10 | 2021-12-14 | 11,989 | $15.03 | $180.2K | 1,256,224 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | M Exercise | 2021-12-10 | 2021-12-14 | 1,000 | $2.15 | $2.1K | 45,475 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | S Sale | 2021-12-10 | 2021-12-14 | 1,000 | $14.76 | $14.8K | 44,475 | SEC↗ |
| Zhang Xiaoyan Michelle | Chief Scientific Officer | A Award deriv | 2021-11-22 | 2021-11-23 | 176,699 | — | $0 | 176,699 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2021-04-15 | 2021-04-15 | 26,838 | — | $0 | 26,838 | SEC↗ |
| Koehler Maria | Director | A Award deriv | 2021-04-15 | 2021-05-03 | 26,838 | — | $0 | 26,838 | SEC↗ |
| Atlas Venture Associates Oppor | 10% Owner | P Buy | 2021-03-30 | 2021-12-14 | 125,000 | $16.00 | $2.00M | 874,634 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | P Buy | 2021-03-30 | 2021-12-14 | 125,000 | $16.00 | $2.00M | 874,634 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 328,907 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 920,484 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 806,752 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 2,257,785 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 680,766 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,905,201 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 68,978 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 130,924 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 68,978 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 130,924 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 328,907 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 920,484 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 806,752 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 2,257,785 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 680,766 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 1,905,201 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion deriv | 2021-03-30 | 2021-04-01 | 5,362,888 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion deriv | 2021-03-30 | 2021-04-01 | 9,499,999 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion deriv | 2021-03-30 | 2021-04-01 | 11,258,117 | — | $0 | 0 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion deriv | 2021-03-30 | 2021-04-01 | 7,863,094 | — | $0 | 0 | SEC↗ |
| Stampacchia Otello | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 12,870,933 | — | $0 | 0 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 9,499,999 | — | $0 | 0 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 11,258,117 | — | $0 | 0 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 7,863,094 | — | $0 | 0 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion deriv | 2021-03-30 | 2021-04-01 | 5,362,888 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 2,034,708 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 551,259 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 2,411,260 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 653,277 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 983,055 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 266,336 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 157,288 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion deriv | 2021-03-30 | 2021-04-13 | 42,614 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 551,259 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 2,411,260 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 983,054 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 653,277 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 2,034,708 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 266,337 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 157,288 | — | $0 | 0 | SEC↗ |
| Bonita David P | Director | C Conversion deriv | 2021-03-30 | 2021-04-14 | 42,614 | — | $0 | 0 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | P Buy | 2021-03-30 | 2021-04-01 | 375,000 | $16.00 | $6.00M | 2,191,425 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-01 | 1,816,425 | — | $0 | 1,816,425 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | P Buy | 2021-03-30 | 2021-04-01 | 48,400 | $16.00 | $774.4K | 117,378 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-01 | 5,083,470 | — | $0 | 5,083,470 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-01 | 130,924 | — | $0 | 130,924 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-01 | 68,978 | — | $0 | 68,978 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-01 | 130,924 | — | $0 | 130,924 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-01 | 5,083,470 | — | $0 | 5,083,470 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-01 | 1,816,425 | — | $0 | 1,816,425 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-01 | 68,978 | — | $0 | 68,978 | SEC↗ |
| Bonita David P | Director | P Buy | 2021-03-30 | 2021-04-01 | 48,400 | $16.00 | $774.4K | 117,378 | SEC↗ |
| Bonita David P | Director | P Buy | 2021-03-30 | 2021-04-01 | 375,000 | $16.00 | $6.00M | 2,191,425 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion | 2021-03-30 | 2021-04-01 | 2,901,609 | — | $0 | 2,901,609 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion | 2021-03-30 | 2021-04-01 | 749,634 | — | $0 | 749,634 | SEC↗ |
| Atlas Venture Associates XI, L | 10% Owner | C Conversion | 2021-03-30 | 2021-04-01 | 1,099,118 | — | $0 | 1,268,213 | SEC↗ |
| Stampacchia Otello | Director | A Award | 2021-03-30 | 2021-04-01 | 450,000 | $16.00 | $7.20M | 2,249,123 | SEC↗ |
| Stampacchia Otello | Director | C Conversion | 2021-03-30 | 2021-04-01 | 1,799,123 | — | $0 | 1,799,123 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion | 2021-03-30 | 2021-04-01 | 1,099,118 | — | $0 | 1,268,213 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion | 2021-03-30 | 2021-04-01 | 2,901,609 | — | $0 | 2,901,609 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | C Conversion | 2021-03-30 | 2021-04-01 | 749,634 | — | $0 | 749,634 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-13 | 1,470,872 | — | $0 | 1,470,872 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-13 | 42,614 | — | $0 | 42,614 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | P Buy | 2021-03-30 | 2021-04-13 | 48,400 | $16.00 | $774.4K | 91,014 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-13 | 5,429,023 | — | $0 | 5,429,023 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | C Conversion | 2021-03-30 | 2021-04-13 | 157,288 | — | $0 | 157,288 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | P Buy | 2021-03-30 | 2021-04-13 | 375,000 | $16.00 | $6.00M | 1,845,872 | SEC↗ |
| Bonita David P | Director | P Buy | 2021-03-30 | 2021-04-14 | 375,000 | $16.00 | $6.00M | 1,845,872 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-14 | 5,429,023 | — | $0 | 5,429,023 | SEC↗ |
| Bonita David P | Director | P Buy | 2021-03-30 | 2021-04-14 | 48,400 | $16.00 | $774.4K | 91,014 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-14 | 157,288 | — | $0 | 157,288 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-14 | 42,614 | — | $0 | 42,614 | SEC↗ |
| Bonita David P | Director | C Conversion | 2021-03-30 | 2021-04-14 | 1,470,872 | — | $0 | 1,470,872 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 1,430,103 | $1.40 | $2.00M | 1,430,103 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 8,938,148 | $1.40 | $12.51M | 8,938,148 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 1,430,103 | $1.40 | $2.00M | 1,430,103 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 8,938,148 | $1.40 | $12.51M | 8,938,148 | SEC↗ |
| Stampacchia Otello | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 12,870,933 | $1.40 | $18.02M | 12,870,933 | SEC↗ |
| FORMELA JEAN FRANCOIS | Director | A Award deriv | 2020-12-21 | 2021-04-01 | 5,362,888 | $1.40 | $7.51M | 5,362,888 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | A Award deriv | 2020-12-21 | 2021-04-13 | 8,938,148 | $1.40 | $12.51M | 8,938,148 | SEC↗ |
| OrbiMed Genesis GP LLC | Director | A Award deriv | 2020-12-21 | 2021-04-13 | 1,430,103 | $1.40 | $2.00M | 1,430,103 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2020-12-21 | 2021-04-14 | 1,430,103 | $1.40 | $2.00M | 1,430,103 | SEC↗ |
| Bonita David P | Director | A Award deriv | 2020-12-21 | 2021-04-14 | 8,938,148 | $1.40 | $12.51M | 8,938,148 | SEC↗ |